TI-233 as a glutamate channel blocker at the crayfish neuromuscular junction

Anomalous voltage dependence of channel blockade at a crustacean glutamate-mediated synapse

1. The voltage dependence and concentration dependence of blockade of glutamate-activated currents by the diquaternary amine, chlorisondamine, were examined in a marine crustacean muscle. 2. Chlorisondamine results in the splitting of focally recorded synaptic current decays into two exponential components. The fast component becomes faster with increases in drug concentration and with hyperpolarization. The slow decay rate is unchanged or faster with hyperpolarization and the relative amplitude of the slow component is increased with hyperpolarization. 3. The alteration of synaptic current decay rates by chlorisondamine over the range of 5 to 100 microM and -80 to -140 mV is quantitatively consistent with a simple channel blockade model with a zero-voltage blocking rate of 6 x 10(5) M-1 s-1 at 12 degrees C with a voltage dependence of about 40 mV per e-fold change. The unblocking rate is about 5 s-1 at 0 mV and increases with hyperpolarization with a voltage dependence of about 30 mV per e-fold change. 4. The dose dependence and voltage dependence of blockade of ionophoretically activated glutamate currents by chlorisondamine are qualitatively consistent with the kinetic estimates. 5. The anomalous voltage dependence of the unblocking process is considered in terms of the possibility that the relief from blockade by chlorisondamine occurs by transit of chlorisondamine through the ion channel opened by glutamate.

Excitatory action of a plant extract, stizolobic acid, in the isolated spinal cord of the rat

Actions of stizolobic acid, stizolobinic acid and their derivatives were examined on the isolated spinal cord of the newborn rat. The responses were recorded from the ventral root. Stizolobic acid and its bromo-derivatives caused a depolarizing response in a dose-dependent manner. Stizolobinic acid was considerably less potent than stizolobic acid. Depolarizing responses to stizolobic acid and its bromo-derivatives were not affected by the existence of Mg2+ and specific N-methyl-D-aspartate (NMDA) antagonists. Kynurenate depressed responses to stizolobic acid. These results suggest that stizolobic acid is a new excitatory amino acid in the mammalian central neurons which binds preferably to other receptors than the NMDA-type receptor.

A new potent channel blocker: effects on glutamate responses at the crayfish neuromuscular junction

The glutamate blocking action of 5-methyl-1-phenyl-2-(3-piperidinopropylamino)-hexane-1-ol (MLV-5860) was studied at the crayfish neuromuscular junction using electrophysiological techniques. The opener muscle of the dactyl in the first leg of the crayfish was used to examine the action of the drug on the glutamate response. MLV-5860 reduced the amplitude of repetitively-induced glutamate potentials in a dose-dependent manner at the crayfish neuromuscular junction and this reduction was time- and activity-dependent. The minimum effective concentration of MLV-5860 to reduce the glutamate response was estimated to be lower than 50 nM, and therefore MLV-5860 is the most powerful glutamate blocker known at the crayfish neuromuscular junction. Pretreatment of the muscle fiber with concanavalin A did not affect the action of MLV-5860. MLV-5860 reduced the amplitude of excitatory junctional potentials (EJPs) and increased the decay rate of extracellularly-recorded EJPs in a dose-dependent manner. Quisqualate responses were also reduced by this drug but the conductance increase of the muscle membrane induced by GABA was not affected. MLV-5860 did not cause a significant change in the input resistance of the opener muscle fiber at concentrations less than 10 microM. The action of the drug is possibly explained in part by the open channel block of the glutamate-activated ion channels. The forward rate constant for channel blockade was estimated from the difference between the decay rate constants of extracellular EJPs in the absence and presence of the drug and the estimated value was 6.5 +/- 1.4 X 10(7) M-1 s-1.